Aimee Vaccine Co., Ltd. announced its interim performance for the six months ended June 30, 2024, showing a slight decrease in revenue by 0.6% and a decrease in gross profit by 10.3%. The loss for the period decreased by 43.6% from RMB 257.4 million to RMB 145.3 million compared to the same period last year. The reduction in research and development expenses by 57.3% is mainly due to the decrease in research and development expenses related to overseas clinical trials. Sales and distribution expenses increased slightly by 3.3%, while administrative expenses increased by 7.4%. The company continues to advance the research and development of new products, including mRNA technology platform-related vaccines, pneumonia vaccines under research, and other vaccines under research. The company is also actively expanding into international markets...Show More

Aimee Vaccine Co., Ltd. announced its interim performance for the six months ended June 30, 2024, showing a slight decrease in revenue by 0.6% and a decrease in gross profit by 10.3%. The loss for the period decreased by 43.6% from RMB 257.4 million to RMB 145.3 million compared to the same period last year. The reduction in research and development expenses by 57.3% is mainly due to the decrease in research and development expenses related to overseas clinical trials. Sales and distribution expenses increased slightly by 3.3%, while administrative expenses increased by 7.4%. The company continues to advance the research and development of new products, including mRNA technology platform-related vaccines, pneumonia vaccines under research, and other vaccines under research. The company is also actively expanding into international markets, having begun registration work in multiple countries and successfully exporting vaccines to countries including Pakistan and Cote d'Ivoire. In addition, the company has strengthened the promotion of its vaccine full-process temperature monitoring series products to enhance product competitiveness. As of June 30, 2024, the company's total cash and cash equivalents, as well as fixed deposits, amounted to RMB 655.3 million, with a net current liability of RMB 433.2 million.